公开(公告)号：US10000558B2

公开(公告)日：2018-06-19

申请号：US15238328

申请日：2016-08-16

Applicant: The University of Hong Kong

Inventor： Stephanie Kwai Yee Ma ,  Man Tong ,  Xin-Yuan Guan

IPC: A61K39/395 ,  C07K16/18 ,  C12Q1/68 ,  C12N15/113 ,  G01N33/50 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/11 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y301/04003 ,  G01N33/5011 ,  G01N33/57438 ,  G01N2333/47 ,  G01N2333/4718 ,  G01N2333/916

Abstract: Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.

公开(公告)号：US09487831B2

公开(公告)日：2016-11-08

申请号：US14485206

申请日：2014-09-12

Applicant: The University of Hong Kong

Inventor： Stephanie Kwai Yee Ma ,  Man Tong ,  Xin-Yuan Guan

IPC: G01N33/574 ,  C12Q1/68 ,  C12N15/113 ,  G01N33/50 ,  C07K16/18

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/11 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y301/04003 ,  G01N33/5011 ,  G01N33/57438 ,  G01N2333/47 ,  G01N2333/4718 ,  G01N2333/916

Abstract: Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.

Abstract translation: 膜联蛋白A3（ANAX3）用作肝细胞癌（HCC）的诊断和预后的生物标志物，并且单独或与其他组合使用针对ANXA3或反义多核苷酸的单克隆抗体针对ANXA3 mRNA用于抑制或治疗HCC 肝癌治疗。 可以施用针对ANXA3的单克隆抗体来抑制肿瘤生长，转移和化学耐药性。

公开(公告)号：US20170037116A1

公开(公告)日：2017-02-09

申请号：US15238328

申请日：2016-08-16

Applicant: The University of Hong Kong

Inventor： Stephanie Kwai Yee Ma ,  Man Tong ,  Xin-Yuan Guan

IPC: C07K16/18 ,  G01N33/574 ,  C07K16/30

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/11 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y301/04003 ,  G01N33/5011 ,  G01N33/57438 ,  G01N2333/47 ,  G01N2333/4718 ,  G01N2333/916

Abstract: Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.

Abstract translation: 膜联蛋白A3（ANAX3）用作肝细胞癌（HCC）的诊断和预后的生物标志物，并且单独或与其他组合使用针对ANXA3或反义多核苷酸的单克隆抗体针对ANXA3 mRNA用于抑制或治疗HCC 肝癌治疗。 可以施用针对ANXA3的单克隆抗体来抑制肿瘤生长，转移和化学耐药性。

公开(公告)号：US20150071933A1

公开(公告)日：2015-03-12

申请号：US14485206

申请日：2014-09-12

Applicant: The University of Hong Kong

Inventor： Stephanie Kwai Yee Ma ,  Man Tong ,  Xin-Yuan Guan

IPC: C12Q1/68 ,  G01N33/574 ,  G01N33/50 ,  C07K16/40 ,  C12N15/113

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/11 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y301/04003 ,  G01N33/5011 ,  G01N33/57438 ,  G01N2333/47 ,  G01N2333/4718 ,  G01N2333/916

Abstract: Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.

Abstract translation: 膜联蛋白A3（ANAX3）用作肝细胞癌（HCC）的诊断和预后的生物标志物，并且单独或与其他组合使用针对ANXA3或反义多核苷酸的单克隆抗体针对ANXA3 mRNA用于抑制或治疗HCC 肝癌治疗。 可以施用针对ANXA3的单克隆抗体来抑制肿瘤生长，转移和化学耐药性。